See other companies on Welcome to the Jungle
23andMe
Genetic testing and DNA analysis
- 501-1000 employees
- Healthcare
- B2C
- Personal health
- Biology
- Sunnyvale, CA
Jump to section
Company mission
To help people access, understand, and benefit from the human genome.
Few candidates hear
back within 2 weeks
10% employee growth in 12 months
Our take
23andMe offers its customers a vision into their ancestry and health through genetic testing carried out via kits sent through the mail. Results can show users their risk of more than 50 health conditions thanks to a tube of saliva at one end and a lot of technology at the other.
This access to genetic insight has helped the company sell more than 15 million test kits in the last 15 years. This remains the core component of the business. Access to millions of customers DNA however has given the company a vast collection of genetic material, allowing 23andMe to expanded into the drug development space where it is collaborating with pharmaceutical giant GlaxoSmithKline.
23andMe is not without competition, with other big names including Ancestry and MyHeritage. However, with a valuation of $3.5 billion, it remains one of the largest, with pockets deep enough to pursue many of its growth programs. In mid-2021, the company went public through a SPAC merger with a company founded by Richard Branson. 23andMe intends to use the merger to invest in its health and therapeutics division.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Comprehensive health, vision, and dental plans
- Dog friendly office
- Family planning, support, and leave for parents
- Mental healthcare
- Student loan assistance
- Volunteer time off
Company values
- Think big - We are a mission-driven company with big dreams of using data to revolutionize health, wellness, and research
- We heart DNA - Deciphering the human genome is the most exciting scientific discovery of our lifetime
- Lead with science - We make evidence-based decisions and use data to better understand wellness and improve disease
- Get to yes or no, quickly - Pioneering often means there is not an obvious path forward, but we also recognize that indecision leads to failure
- Behind every data point is a human being - In each drop of spit lies a whole story of ancestry, health & connectedness
- We’re in this together - Diversity and opportunity matter – we know that great ideas come from everywhere and that everyone contributes to our success
Funding (last 2 of 10 rounds)
Dec 2020
$82.5m
SERIES F
Jul 2018
$300m
GROWTH EQUITY VC
Total funding: $802.9m
This company has top investors
Leadership
Anne Wojcicki
(CEO)They studied Biology at Yale before working as a Healthcare Analyst for Investor AB, Ardsley Partners, Andor Capital, and Passport Capital for a combined 7 years. They leveraged this clinical experience to found 23andMe in 2006.
Articles
Jobs (2)
Marketing
Product